RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) COMBINED CONDITIONING REGIMEN FOR ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT) IN STANDARD-RISK MYELOID-LEUKEMIA

We previously suggested that using a combined conditioning regimen inc luding rhG-CSF with allogeneic BMT in refractory AML and CML in blast crisis might reduce the rate of relapse and improve disease-free survi val, without any major side effects, In this study, we used the same p rotocol for 10 AML patients in complete remission (CR) and 6 CML patie nts in the chronic phase (CP), We compared disease-free survival as we ll as toxic side effects of the regimen with 6 AML patients in CR and 6 CIVIL patients in CP treated with chemoradiotherapy without G-CSF. T he conditioning regimen consisted of TBI and high-dose AraC, RhG-CSF w as infused continuously at a dose of 5 mu g/kg/day, starting 24 hr bef ore the initial dose of total body irradiation (TBI) until the end of AraC therapy, In all 28 cases, there were no early stage deaths due to regimen-related toxicity (557), None of the 10 AML cases treated with the G-CSF combined regime relapsed, In 6 AML cases treated convention ally without G-CSF, one patient died of infection and another relapsed , There were no relapses in either CML group, In the combined G-CSF gr oup, one patient died of interstitial pneumonitis 48 days after BMT, w hile the rest of the CML cases are still alive. There were no relapses with rhG-CSF and no serious adverse effects in terms of RRT, acute gr aft vs. host disease (GVHD), or leukocyte recovery. (C) 1998 Wiley-Lis s, Inc.